Ber-H2 (anti-CD30)-saporin immunotoxin: A new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: In vitro evaluation

P. L. Tazzari; A. Bolognesi; D. De Totero; B. Falini; R. M. Lemoli; M. R. Soria; S. Pileri; M. Gobbi; H. Stein; L. Flenghi; M. F. Martelli; F. Stirpe

Ber-H2 (anti-CD30)-saporin immunotoxin: A new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: In vitro evaluation

P. L. Tazzari, A. Bolognesi, D. De Totero, B. Falini, R. M. Lemoli, M. R. Soria, S. Pileri, M. Gobbi, H. Stein, L. Flenghi, M. F. Martelli, F. Stirpe

Research output: Contribution to journal › Article › peer-review

Abstract

An immunotoxin containing an anti-CD30 monoclonal antibody (Ber-H2) and saporin, a ribosome-inactivating protein type 1, is described. It specifically inhibits protein synthesis by Hodgkin derived target cell lines with a very high efficiency (IC₅₀ ranging from 5 x 10^-12 M to 5 x 10^-14 M, as saporin), while irrelevant immunotoxins do not. Present results suggest that this immunotoxin could be used for in vivo therapy as well as for ex vivo bone marrow purging in Hodgkin's disease and CD30+ lymphomas.

Original language	English
Pages (from-to)	203-211
Number of pages	9
Journal	British Journal of Haematology
Volume	81
Issue number	2
Publication status	Published - 1992

ASJC Scopus subject areas

Hematology

Cite this

@article{d7e98dd6fb10403799b9095ea3569b97,

title = "Ber-H2 (anti-CD30)-saporin immunotoxin: A new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: In vitro evaluation",

abstract = "An immunotoxin containing an anti-CD30 monoclonal antibody (Ber-H2) and saporin, a ribosome-inactivating protein type 1, is described. It specifically inhibits protein synthesis by Hodgkin derived target cell lines with a very high efficiency (IC50 ranging from 5 x 10-12 M to 5 x 10-14 M, as saporin), while irrelevant immunotoxins do not. Present results suggest that this immunotoxin could be used for in vivo therapy as well as for ex vivo bone marrow purging in Hodgkin's disease and CD30+ lymphomas.",

author = "Tazzari, {P. L.} and A. Bolognesi and {De Totero}, D. and B. Falini and Lemoli, {R. M.} and Soria, {M. R.} and S. Pileri and M. Gobbi and H. Stein and L. Flenghi and Martelli, {M. F.} and F. Stirpe",

year = "1992",

language = "English",

volume = "81",

pages = "203--211",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley & Sons, Ltd (10.1111)",

number = "2",

}

TY - JOUR

T1 - Ber-H2 (anti-CD30)-saporin immunotoxin

T2 - A new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: In vitro evaluation

AU - Tazzari, P. L.

AU - Bolognesi, A.

AU - De Totero, D.

AU - Falini, B.

AU - Lemoli, R. M.

AU - Soria, M. R.

AU - Pileri, S.

AU - Gobbi, M.

AU - Stein, H.

AU - Flenghi, L.

AU - Martelli, M. F.

AU - Stirpe, F.

PY - 1992

Y1 - 1992

N2 - An immunotoxin containing an anti-CD30 monoclonal antibody (Ber-H2) and saporin, a ribosome-inactivating protein type 1, is described. It specifically inhibits protein synthesis by Hodgkin derived target cell lines with a very high efficiency (IC50 ranging from 5 x 10-12 M to 5 x 10-14 M, as saporin), while irrelevant immunotoxins do not. Present results suggest that this immunotoxin could be used for in vivo therapy as well as for ex vivo bone marrow purging in Hodgkin's disease and CD30+ lymphomas.

AB - An immunotoxin containing an anti-CD30 monoclonal antibody (Ber-H2) and saporin, a ribosome-inactivating protein type 1, is described. It specifically inhibits protein synthesis by Hodgkin derived target cell lines with a very high efficiency (IC50 ranging from 5 x 10-12 M to 5 x 10-14 M, as saporin), while irrelevant immunotoxins do not. Present results suggest that this immunotoxin could be used for in vivo therapy as well as for ex vivo bone marrow purging in Hodgkin's disease and CD30+ lymphomas.

UR - http://www.scopus.com/inward/record.url?scp=0026643025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026643025&partnerID=8YFLogxK

M3 - Article

C2 - 1322690

AN - SCOPUS:0026643025

VL - 81

SP - 203

EP - 211

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -

Ber-H2 (anti-CD30)-saporin immunotoxin: A new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: In vitro evaluation

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this